Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Drepanostat
- Development stage
- Unknown
- Lead developer
- Bolar Pharmaceuticals
- Administration
- Oral
01
Overview
Drepanostat is a licensed consumer health product marketed by Bolar Pharmaceuticals for the management of sickle cell disease. It is categorized as a phytomedicine or herbal supplement intended to reduce the frequency and severity of vaso-occlusive crises in patients with sickle cell anemia. The product is primarily distributed in the Nigerian market and is part of Bolar's portfolio of consumer health brands, which includes various vitamins and herbal remedies. As a licensed health product rather than a proprietary R&D candidate, it does not have publicly disclosed clinical trial phases or specific molecular targets in conventional pharmaceutical databases.
- Brand names
- Drepanostat
- Other names
- Drepanostat
Beyond the preview
Go deeper on Drepanostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Drepanostat.